1. Home
  2. ERAS vs MFH Comparison

ERAS vs MFH Comparison

Compare ERAS & MFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • MFH
  • Stock Information
  • Founded
  • ERAS 2018
  • MFH 2011
  • Country
  • ERAS United States
  • MFH United States
  • Employees
  • ERAS N/A
  • MFH N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • MFH Finance: Consumer Services
  • Sector
  • ERAS Health Care
  • MFH Finance
  • Exchange
  • ERAS Nasdaq
  • MFH Nasdaq
  • Market Cap
  • ERAS 432.6M
  • MFH 382.7M
  • IPO Year
  • ERAS 2021
  • MFH N/A
  • Fundamental
  • Price
  • ERAS $1.37
  • MFH $5.54
  • Analyst Decision
  • ERAS Strong Buy
  • MFH
  • Analyst Count
  • ERAS 6
  • MFH 0
  • Target Price
  • ERAS $4.83
  • MFH N/A
  • AVG Volume (30 Days)
  • ERAS 1.8M
  • MFH 62.8K
  • Earning Date
  • ERAS 03-20-2025
  • MFH 04-21-2025
  • Dividend Yield
  • ERAS N/A
  • MFH N/A
  • EPS Growth
  • ERAS N/A
  • MFH N/A
  • EPS
  • ERAS N/A
  • MFH N/A
  • Revenue
  • ERAS N/A
  • MFH $716,863.00
  • Revenue This Year
  • ERAS N/A
  • MFH N/A
  • Revenue Next Year
  • ERAS N/A
  • MFH N/A
  • P/E Ratio
  • ERAS N/A
  • MFH N/A
  • Revenue Growth
  • ERAS N/A
  • MFH 119.50
  • 52 Week Low
  • ERAS $1.23
  • MFH $1.03
  • 52 Week High
  • ERAS $3.45
  • MFH $8.86
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 39.36
  • MFH 42.82
  • Support Level
  • ERAS $1.40
  • MFH $5.73
  • Resistance Level
  • ERAS $1.61
  • MFH $6.42
  • Average True Range (ATR)
  • ERAS 0.11
  • MFH 0.61
  • MACD
  • ERAS 0.01
  • MFH 0.04
  • Stochastic Oscillator
  • ERAS 4.00
  • MFH 44.79

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About MFH Mercurity Fintech Holding Inc.

Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.

Share on Social Networks: